# Efficacy of Phosphatidylserine Enriched With n-3 PUFA Supplementation on ADHD in Children With Epilepsy

> **NCT02348073** · PHASE3 · COMPLETED · sponsor: **Hospices Civils de Lyon** · enrollment: 77 (actual)

## Conditions studied

- Attention Deficit Disorder With Hyperactivity
- ADHD Inattention or Mixed Type
- Epilepsy
- Child

## Interventions

- **DRUG:** Vayarin®, supplementation of n-3 PUFA
- **DRUG:** PLACEBO

## Key facts

- **NCT ID:** NCT02348073
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2018-10
- **Final completion:** 2018-10
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2025-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02348073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02348073, "Efficacy of Phosphatidylserine Enriched With n-3 PUFA Supplementation on ADHD in Children With Epilepsy". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT02348073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*